Lexeo Therapeutics, Inc.

NasdaqGM:LXEO Stock Report

Market Cap: US$207.7m

Lexeo Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Lexeo Therapeutics has a total shareholder equity of $139.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $173.9M and $34.5M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$157.02m
EquityUS$139.33m
Total liabilitiesUS$34.54m
Total assetsUS$173.87m

Recent financial health updates

Recent updates

We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

Oct 11
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Jul 16

We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

Jun 18
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Apr 09

Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's

Jan 29

Financial Position Analysis

Short Term Liabilities: LXEO's short term assets ($159.5M) exceed its short term liabilities ($26.8M).

Long Term Liabilities: LXEO's short term assets ($159.5M) exceed its long term liabilities ($7.7M).


Debt to Equity History and Analysis

Debt Level: LXEO is debt free.

Reducing Debt: LXEO had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LXEO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LXEO has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 26.5% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:58
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lexeo Therapeutics, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Yevgeniya LivshitsChardan Capital Markets, LLC
Mitchell KapoorH.C. Wainwright & Co.